Medical Dosimetry
Volume 33, Issue 3 , Pages 226-233 , Autumn 2008

The Detectability and Localization Accuracy of Implanted Fiducial Markers Determined on In-Room Computerized Tomography (CT) and Electronic Portal Images (EPI)

Received 25 August 2007 ,Accepted 27 December 2007.

References 

  1. Australian Institute of Health and Welfare (AIHW) and Australasian Association of Cancer Registries. Cancer in Australia 2001. In: Canberra: AIHW; 2004;p. 1–157
  2. van der Heide UA, Kotte ANTJ, Dehnad H, et al. Analysis of fiducial marker-based position verification in the external beam radiotherapy of patients with prostate cancer. Radiother. Oncol. 2007;82:38–45
  3. Chung PWM, Haycocks T, Brown T, et al. On-line aSi portal imaging of implanted fiducial markers for the reduction of interfraction error during conformal radiotherapy of prostate carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2004;60:329–334
  4. Wu J, Haycocks T, Alasti H, et al. Positioning errors and prostate motion during conformal prostate radiotherapy using on-line isocentre set-up verification and implanted prostate markers. Radiother. Oncol. 2001;61:127–133
  5. Dehnad H, Nederveen AJ, van der Heide UA, et al. Clinical feasibility study for the use of implanted gold seeds in the prostate as reliable positioning markers during megavoltage irradiation. Radiother. Oncol. 2003;67:295–302
  6. Kitamura K, Shirato H, Shimizu S, et al. Migration of the internal fiducial gold marker implanted into prostate and liver treated with real-time tumor-tracking radiation treatment (RTRT). Int. J. Radiat. Oncol. Biol. Phys. 2000;48(Suppl 1):343–344
  7. Kupelian PA, Willoughby TR, Meeks SL, et al. Intraprostatic fiducials for localization of the prostate gland: Monitoring intermarker distances during radiation therapy to test for marker stability. Int. J. Radiat. Oncol. Biol. Phys. 2005;62:1291–1296
  8. Pouliot J, Aubin M, Langen KM, et al. (Non)-migration of radiopaque markers used for on-line localization of the prostate with an electronic portal imaging device. Int. J. Radiat. Oncol. Biol. Phys. 2003;56:862–866
  9. Litzenberg D, Dawson LA, Sandler H, et al. Daily prostate targeting using implanted radiopaque markers. Int. J. Radiat. Oncol. Biol. Phys. 2002;52:699–703
  10. Crook JM, Raymond Y, Salhani D, et al. Prostate motion during standard radiotherapy as assessed by fiducial markers. Radiother. Oncol. 1995;37:35–42
  11. Schallenkamp JM, Herman MG, Kruse JJ, et al. Prostate position relative to pelvic bony anatomy based on intraprostatic gold markers and electronic portal imaging. Int. J. Radiat. Oncol. Biol. Phys. 2005;63:800–811
  12. Henry AM, Stratford J, Davies J, et al. An assessment of clinically optimal gold marker length and diameter for pelvic radiotherapy verification using an amorphous silicon flat panel electronic portal imaging device. Br. J. Radiol. 2005;78:737–741
  13. Siemens Medical Solutions USA, Inc.. Optivue 500 and Optivue 1000ST Fully Automated Patient Positioning Systems-Specifications. 2006;
  14. Kitamura K, Shirato H, Shimizu S, et al. Registration accuracy and possible migration of internal fiducial gold marker implanted in prostate and liver treated with real-time tumor-tracking radiation therapy (RTRT). Radiother. Oncol. 2002;62:275–281
  15. Moseley DJ, White EA, Wiltshire KL, et al. Comparison of localisation performance with implanted fiducial markers and cone-beam computed tomography for on-line image-guided radiotherapy of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 2007;67:942–953
  16. Pollack A, Hanlon AL, Horwitz EM, et al. Prostate cancer radiotherapy dose response: An update of the Fox Chase Experience. J. Urol. 2004;171:1132–1136

PII: S0958-3947(08)00030-7

doi: 10.1016/j.meddos.2007.12.002

Medical Dosimetry
Volume 33, Issue 3 , Pages 226-233 , Autumn 2008

Article Tools

* Image Usage & Resolution